Existing drug treatments cannot significantly shorten the clinical cure time of children with COVID-19

J Infect Dev Ctries. 2020 Sep 30;14(9):963-967. doi: 10.3855/jidc.13491.

Abstract

Introduction: COVID-19 has become a global health security issue, it has caused more than half a million deaths worldwide so far, the treatment strategies are the most concerned issues for clinicians. In this study, the treatments and outcomes in 40 pediatric patients diagnosed with COVID-19 and treated with different drugs were evaluated.

Methodology: All cases were diagnosed with COVID-19 nucleic acid positive by using RT-PCR or clinical manifestations, imaging specific characteristics and epidemiological clinical diagnosis. The biological information and first symptom of all cases were collect. A variety of treatments were employed and the outcomes were evaluated by Cox regression analysis. Multivariable analysis was performed to evaluate cure rate at 14 days with different drug treatment.

Results: The average length of hospital stay was 10.4 days. The cure rate was increased with the treatment time extended and 90% of pediatric patients were cured and discharged after 14 days' treatment. And multivariable analysis results proved that none of the covariates were related to the cure rate at 14 days with different drug treatment since p values were over 0.05.

Conclusions: Multivariable analysis suggested that the present drug treatments cannot significantly shorten the clinical cure time and improve the cure rate of children with COVID-19.

Keywords: COVID-19; Coronavirus disease 2019; cure rate; different treatment agents; pediatric patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus* / isolation & purification
  • Child
  • Child, Preschool
  • China
  • Clinical Laboratory Techniques
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Multivariate Analysis
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Proportional Hazards Models
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Antiviral Agents

Supplementary concepts

  • COVID-19
  • COVID-19 diagnostic testing
  • COVID-19 drug treatment
  • severe acute respiratory syndrome coronavirus 2